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Red blood cell transfusions remain one of the cornerstones in sup-portive care of lower-risk patients with myelodysplastic syn-dromes. We hypothesized that patients develop oxidant-mediated
tissue injury through the formation of toxic iron species, caused either by
red blood cell transfusions or by ineffective erythropoiesis. We analyzed
serum samples from 100 lower-risk patients with myelodysplastic syn-
dromes at six-month intervals for transferrin saturation, hepcidin-25,
growth differentiation factor 15, soluble transferrin receptor, non-trans-
ferrin bound iron and labile plasma iron in order to evaluate temporal
changes in iron metabolism and the presence of potentially toxic iron
species and their impact on survival. Hepcidin levels were low in 34
patients with ringed sideroblasts compared to 66 patients without.
Increases of hepcidin and non-transferrin bound iron levels were visible
early in follow-up of all transfusion-dependent patient groups. Hepcidin
levels significantly decreased over time in transfusion-independent
patients with ringed sideroblasts. Increased soluble transferrin receptor
levels in transfusion-independent patients with ringed sideroblasts con-
firmed the presence of ineffective erythropoiesis and suppression of hep-
cidin production in these patients. Detectable labile plasma iron levels in
combination with high transferrin saturation levels occurred almost
exclusively in patients with ringed sideroblasts and all transfusion-
dependent patient groups. Detectable labile plasma iron levels in trans-
fusion-dependent patients without ringed sideroblasts were associated
with decreased survival. In conclusion, toxic iron species occurred in all
transfusion-dependent patients and in transfusion-independent patients
with ringed sideroblasts. Labile plasma iron appeared to be a clinically
relevant measure for potential iron toxicity and a prognostic factor for
survival in transfusion-dependent patients. clinicaltrials.gov Identifier:
00600860.   
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ABSTRACT
Introduction 
Myelodysplastic syndromes (MDS) are a heterogeneous
group of acquired clonal hematopoietic stem cell disorders
that are characterized by abnormal differentiation and
maturation of hematopoietic cells, bone marrow failure
and genetic instability with an enhanced risk of progres-
sion to acute myeloid leukemia.1 The European MDS
(EUMDS) registry is a prospective, observational registry
which was established in 2007 in order to collect data on
low and intermediate-1-risk MDS patients, who represent
the lower-risk MDS population, comprising approximate-
ly seventy percent of the overall MDS population.2,3 The
majority of lower-risk MDS patients (51% in the EUMDS
Registry)3 become transfusion-dependent, usually early
after diagnosis. With an expected median survival of 2.4 to
11.8 years, these patients are prone to long-term accumu-
lation of iron due to red blood cell (RBC) transfusions.4-8
Iron overload may also occur in MDS patients who do not
receive RBC transfusions, due to the stimulation of intes-
tinal iron absorption, mediated through the suppression of
hepcidin production in patients with ineffective erythro-
poiesis.9 Patients with ringed sideroblasts (MDS-RS) are of
special interest in this context, considering their pro-
nounced ineffective erythropoiesis.6,7,10,11
The toxic effects of iron overload in other iron loading
diseases, such as hereditary hemochromatosis11 and the
thalassemia syndromes12 are well known, but the conse-
quences in MDS remain to be elucidated. MDS patients
are generally older than patients with other iron loading
disorders.13 Their exposure may not be long enough to
develop classical tissue damage due to iron overload, but
they may suffer from oxidative stress caused by toxic iron
molecules. Moreover, iron toxicity might be restricted to
specific subgroups of MDS patients; those receiving RBC
transfusions and a subgroup of patients with MDS-RS and
increased ineffective erythropoiesis.5,13
A greater insight into the pathophysiology of iron
metabolism in MDS might be obtained through an opti-
mized diagnostic work-up and monitoring by specific iron
metabolism markers, including hepcidin, growth differen-
tiation factor 15 (GDF15), soluble transferrin receptor
(sTFR),  and the recently introduced serum toxic iron
species, namely non-transferrin bound iron (NTBI) and
labile plasma iron (LPI).14-18 The most important regulator
of systemic iron metabolism is hepcidin, a 25-aminoacid
peptide hormone, produced predominantly by the hepa-
tocytes. Hepcidin triggers internalization and lysosomal
degradation of ferroportin, a membrane bound cellular
iron exporter present on macrophages and the basolateral
site of enterocytes that releases iron into the circula-
tion.19,20 Hepcidin is suppressed in hypoxia and with
increased erythropoietic iron demand and is upregulated
in case of inflammation and increased circulating iron lev-
els and elevated body iron stores.5,20,21
GDF15 is a protein produced by erythroid precursors
and has been reported to be involved in the communica-
tion between bone marrow and liver in case of an
increased erythroid demand, functioning as a suppressor
of hepcidin synthesis, as shown for β-thalassemia.5,9,22
However, its role in MDS is still a matter of debate due to
conflicting results.5,11,22-25 Twisted gastrulation factor 1
(TWSG1) and erythroferrone (ERFE) are also reported to
have a suppressive function in hepatic hepcidin produc-
tion, however, validated human assays are not available.9
Of additional interest in iron homeostasis is sTFR. The
serum concentration of sTFR is proportional to the quan-
tity of the transferrin receptors 1 (TfR1) on cellular mem-
branes, especially on erythroid precursors, and is a valu-
able parameter of erythroid mass and iron supplies.26,27
Among others, sTFR levels are elevated in case of high
erythroid proliferation rates, especially in combination
with adequate iron supply,27 as in diseases characterized
by ineffective erythropoiesis, such as β-thalassemia syn-
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Table 1. Frequency, median and quartiles of iron substudy parameters overall, by transfusion status and MDS subtype at first sample.
Transfusion Ring Sideroblasts
Total Independent Dependent No Yes
N Median N Median N Median N Median N Median
(p10-p90) (p10-p90) (p10-p90) (p10-p90) (p10-p90)
Hemoglobin (g/dl) 100 10.2 (8.3 - 12.4) 85 10.3 (8.6 - 12.6) 15 9.3 (6.4 - 10.9) 66 10.4 (8.5 - 12.5) 34 9.9 (7.3 - 12.1)
White blood cells (109/L) 100 4.8 (2.4 - 8.7) 85 5.1 (2.5 - 8.7) 15 3.8 (2.3 - 10.7) 66 3.9 (2.3 - 7.4) 34 6.0 (3.9 - 11.4)
Platelets (109//L) 99 212 (94 - 475) 84 218 (97 - 475) 15 158 (87 - 463) 66 168 (89 - 341) 33 316 (169 - 501)
Serum Iron (µmol/L) 100 20 (12 - 38) 85 19 (12 - 34) 15 26.0 (4.0 - 47.0) 66 17 (10 - 26) 34 30 (16 - 45)
Ferritin (μg/L) 100 287 (48 - 982) 85 264 (49 - 692) 15 634 (20 - 1897) 66 246 (36 - 665) 34 376(127 -1242)
Transferrin saturation (%) 100 36 (19 - 87) 85 35 (19 - 81) 15 52 (13 - 93) 66 31 (17 - 61) 34 59 (25 - 93)
Hepcidin (nmol/L) 99 4.5 (1.1 - 21.7) 84 4.2 (1.2 - 13.8) 15 6.8 (0.5 - 53.7) 66 4.7 (1.1 - 24.2) 33 4.2 (1.2 - 10.3)
Soluble transferrin receptor (mg/L) 100 1.3 (0.7 - 2.8) 85 1.3 (0.8 - 2.8) 15 0.9 (0.6 - 3.0) 66 1.2 (0.7 - 2.7) 34 1.5 (0.8 - 3.1)
C-reactive protein (mg/L) 100 5.0 (4.0 - 11.5) 85 5.0 (4.0 - 11.0) 15 5.0 (4.0 - 139.0) 66 5.0 (4.0 - 13.0) 34 5.0 (4.0 - 10.0)
Non transferrin bound iron (µmol/L) 100 0.7 (0.1 - 3.0) 85 0.6 (0.1 - 2.9) 15 1.0 (0.1 - 3.4) 66 0.5 (0.1 - 1.8) 34 1.2 (0.3 - 3.8)
Labile plasma iron (μmol/L) 100 0.1 (0.0 - 0.2) 85 0.1 (0.0 - 0.2) 15 0.1 (0.0 - 0.3) 66 0.1 (0.0 - 0.2) 34 0.1 (0.0 - 0.3)
Growth differentiation  100 2193 85 2140 15 2823 66 1844 34 2888 
factor 15 (ng/L) (952 - 5663) (921 - 6084) (1232 - 5026) (921 - 4828) (1026 -10361) 
dromes, and levels are suppressed in case of decreased
erythropoietic activity, as in anemia of chronic disease,
and diseases with erythroid hypoplasia.20,25,28 Earlier stud-
ies showed that sTFR levels are increased in MDS-RS,5
including SF3B1-positive MDS patients.11 
NTBI concentrations are only sporadically present with
transferrin saturations (TSAT) <70% and increase sharply
when the saturation of transferrin with iron exceeds
70%.29 Chemically, NTBI consists of iron that is rather
loosely bound to albumin or low molecular weight metal
complexing  groups.30,31 The NTBI complexes may be
taken up by specific NTBI transporters in the liver, pan-
creas, and heart and contribute to oxidant-mediated cellu-
lar injury in these tissues.17,32 LPI is thought to be the NTBI
fraction that is mostly responsible for tissue injury, since it
is readily available to participate in redox cycling, causing
oxidative damage to cellular membranes, proteins and
DNA.15,33 It has been proposed that plasma NTBI is an
important early indicator of extra-hepatic iron toxicity in
β-thalassemia major.34,35
Improved insights in the levels and roles of key players
of iron metabolism during treatment with transfusions in
the various MDS subtypes may provide leads for novel
diagnostic and iron reducing treatment strategies. The
prospective study of the EUMDS registry was initiated in
order to provide a better understanding of the pathophys-
iology and prognostic value of iron overload and iron-
mediated oxidative stress as well as possibly important
markers in iron homeostasis over time in MDS. To this
end, we evaluated serum ferritin, iron, transferrin satura-
tion, hepcidin-25, GDF15, sTFR, NTBI and LPI levels over
time in lower-risk MDS patients and their relation with
regard to the World Health Organization (WHO) 2001
subtype and transfusion history. We identified detectable
LPI levels as a new important prognostic factor for survival
in patients with MDS-RS or lower-risk MDS patients
treated with regular RBC transfusions.
Methods 
Study design and participants 
Patients were eligible to be included in the EUMDS registry if
they were newly diagnosed with MDS according to the WHO 2001
classification and a low or intermediate-1 score according to the
International Prognostic Scoring System (IPSS). Two patients with
IPSS intermediate-2 or high-risk patients with secondary or therapy-
related MDS were excluded from this registry. The ethics commit-
tees of all participating countries and centers approved the protocol.
Patients were required to provide written informed consent. 
Serum samples were collected prospectively, at registration and
at 6-month intervals, from 109 patients from six countries who
participated in this study from April 2008 to December 2010.
Samples from nine patients had to be excluded due to technical
reasons, see Online Supplementary Information for details. The total
number of analyzed serum samples was 454.
Toxic iron species in lower-risk MDS
haematologica | 2018; 103(1) 71
Figure 1. LPI and NTBI correlated to TSAT and ferritin in different patient groups. (A) Relation between LPI and TSAT. (B) Relation between NTBI and TSAT. (C) Relation
between LPI and ferritin. (D) Relation between NTBI and ferritin. Each dot represents one sample (median: 5 samples/patient). RS: ring sideroblastic; TI: transfu-
sion-independent; TD: transfusion-dependent.  
A
B
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Biochemical assays
The iron parameters in this substudy were analyzed centrally at
the department of Laboratory Medicine of the Radboudumc,
Nijmegen, The Netherlands. Detailed information regarding these
iron parameters is described in the Online Supplementary
Information.
Measurement of serum NTBI consisted of the chelation-ultrafil-
tration-detection approach based on the prior mobilization of
serum NTBI by weak iron-mobilizing chelators, such as nitrilotri-
acetate (NTA), at 80 mM. The chelated NTBI was separated from
transferrin-bound iron by ultrafiltration and detected by colorime-
try.36 The lower limit of detection (LLOD) of the NTBI assay was
0.47 μmol/L. The LPI measurement was based on the measure-
ment of the redox-active and readily chelatable fraction of NTBI.
This assay measures iron-catalyzed radical generation in the pres-
ence of a low ascorbate concentration. Radical generation was
measured with the fluorogenic redox sensitive probe dihydrorho-
damine (DHR) 123, and iron-catalyzed radical generation was cal-
culated by subtracting the radical generation in the presence of 50
μmol/L of the bidendate iron chelator deferiprone (DFO, the LPI
DHR oxidation that is NOT iron dependent).37 The LLOD of the
LPI assay was 0.24 μmol/L.
Statistical analysis
Standard descriptive techniques were used to assess the associ-
ation between the iron parameters including Spearman's rank cor-
relation coefficients. Where NTBI or LPI was below LLOD, values
were randomly drawn from a univariate distribution in the range
from zero to the LLOD. Overall survival (OS) was defined as the
time from date of diagnosis to death, or for subjects still alive and
censored, to the date of the last visit when a sample was available.
Cox proportional hazards regression models and Kaplan–Meier
survival curves with time-dependent covariates38 were used in
time-to-event analyses to assess the impact of LPI levels, NTBI and
TSAT by transfusion status on survival. All variables were treated
as time-varying covariates in the model by assessing the levels of
the parameters (LPI, NTBI: <LLOD vs. elevated, TSAT <80% vs.
≥80%) and transfusion status (transfused vs. not transfused) at
each visit. LPI and NTBI levels >LLOD were considered abnormal.
Once a subject had received a transfusion, they were classified as
transfused for the remaining time. Hazard ratios (HR) and 95%
confidence intervals (95% CI) are reported for both univariate and
multivariate models. In the case of multivariate analyses, the addi-
tional covariates included were age at diagnosis, IPPS-revised
(IPSS-R) category and usage of erythroid stimulating agents (ESA).
All analyses were undertaken in Stata 14 (StataCorp, College
Station, TX, USA). 
Results
Patient characteristics 
The median age of all patients at registration was 73
years (range: 43-95 years). The majority of the patients
were male; 64% (n=64). The IPSS risk groups of the 100
patients in the study were: low 47%, intermediate-1 41%,
and unknown 12%. The IPSS-R risk groups were: very low
32%, low 41%, intermediate 8%, high 3%, and unknown
16%. WHO 2001 MDS-subtypes were refractory cytope-
nia with multilineage dysplasia (RCMD; 37%), refractory
anemia with ring sideroblasts (RARS; 30%), refractory ane-
mia (RA; 18%), refractory anemia with excess blasts
(RAEB; 7%), 5q-syndrome (4%) and refractory cytopenia
with multilineage dysplasia and ringed sideroblasts
(RCMD-RS; 4%).  Fourteen percent of the patients were
transfusion-dependent at registration (n=14). No patients
received iron chelation therapy at the time of registration.
Six patients received iron chelation therapy during this
observation period (Online Supplementary Table S1). The
median number of samples available per patient was 5
(range: 1-7), and the median follow-up period was 5.8
years. OS and progression-free survival (PFS) in our study
population were 4.8 and 4.6 years, respectively. Nineteen
patients died, including 5 patients after progression and 9
patients from causes possibly related to MDS (hemorrhage
2, infection 5, and cardiovascular 2) (Online Supplementary
Table S2).
Iron parameters 
Median ferritin levels were elevated (>250 μg/l) at regis-
tration in all patient groups, but the highest median levels
were observed in the transfusion-dependent (TD) groups
(Table 1). Median serum iron levels were within reference
range (12-30 μmol/L) in all patient groups at registration.
Overall, median TSAT was within reference range (<45%)
at registration, with the exception of TD MDS-RS patients
(Table 2). Median hepcidin levels were within reference
range in all patient groups at registration, but TD patients
had significantly higher hepcidin levels compared to trans-
fusion-independent (TI) patients (P<0.001). Ferritin levels
correlated significantly with hepcidin levels (r=0.55,
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Figure 2 Survival according to LPI (A) or NTBI (B) and transfusion status. LPI,
NTBI and transfusion status were analyzed as time dependent factors, implicat-
ing that patients may switch groups over time according to the LPI/NTBI and
transfusion status at each specific time point. LLOD: lower limit of detection; TI:
transfusion-independent; TD: transfusion-dependent; LPI: labile plasma iron;
NTBI: non-transferrin bound iron.   
A
B
P<0.001). The median GDF15 levels were elevated in the
RS subgroup only. NTBI levels above LLOD (>0.47
µmol/L) occurred in all patient groups at registration with
the highest levels present in MDS-RS patients. sTFR levels
were within the reference range (0.8-1.8 mg/L) at registra-
tion, and the highest levels were observed in TI MDS-RS
patients (Table 2). The median LPI levels were below
LLOD in all patient groups at registration (<0.24 mol/L),
except in TD MDS-RS patients. Median C-reactive protein
(CRP) levels were below the upper limit of the reference
range (<10 mg/L) in all groups at all time points (Table 1)
and the majority of patients with CRP levels above 50
mg/L were TD. CRP levels correlated positively with hep-
cidin levels (r = 0.30, P<0.001) and ferritin levels (r=0.22,
P<0.001). 
Impact of MDS subtype and transfusions on iron
parameters over time 
The impact of transfusions and MDS subtype (RS vs.
non-RS) on TSAT, hepcidin, GDF15, NTBI and LPI levels
over time is shown in Table 2. Both serum ferritin and
serum iron levels increased significantly (r=0.59, P<0.001
and r=0.32, P<0.001, respectively) with a cumulative num-
ber of transfused units over time in TD patients (Online
Supplementary Table S3) as well as in RS patients (Online
Supplementary Table S4). TSAT remained stable and within
Toxic iron species in lower-risk MDS
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Table 2. Frequency, median and quartiles of iron parameters by transfusion status per MDS subtype at registration, 1 year and 2 years follow-up.
                                                                                 Registration 1 year follow-up 2 years follow-up
                                                         N                  Median(p10-p90) N Median(p10-p90) N Median(p10-p90)
Transferrin
saturation (%)                                        100                     35.6 (19.0 - 87.4) 78 34.4 (16.4 - 92.9) 64 37.5 (22.2 - 94.3)
MDS non-RS: TI                                        56                      32.8 (17.1 - 55.6) 32 28.4 (17.4 - 59.1) 26 30.1 (18.8 - 54.2)
MDS non-RS: TD                                      10                       28.7 (8.5 - 77.9) 21 36.8 (14.0 - 89.1) 17 39.3 (20.4 - 97.7)
MDS-RS: TI                                                29                      48.8 (24.6 - 92.5) 16 36.4 (20.8 - 86.4) 9 35.6 (23.9 - 92.6)
MDS-RS: TD                                               5                      90.0 (53.1 - 120.4) 9 93.6 (42.1 - 110.6) 12 93.1 (71.7 - 97.6)
Hepcidin (nmol/L)                                  99                        4.5 (1.1 - 21.7) 78 5.6 (1.2 - 19.6) 65 5.2 (1.0 - 19.6)
MDS non-RS: TI                                        56                        4.5 (1.7 - 22.1) 32 4.3 (1.5 - 11.8) 26 4.6 (0.9 - 13.6)
MDS non-RS: TD                                      10                        4.9 (0.5 - 75.9) 21 17.3 (0.5 - 29.2) 17 9.2 (1.3 - 28.4)
MDS-RS: TI                                                28                         3.8 (1.0 - 8.7) 16 3.4 (0.5 - 5.8) 9 2.9 (0.8 - 12.2)
MDS-RS: TD                                               5                        10.3 (3.8 - 15.9) 9 9.2 (3.8 - 14.4) 13 5.2 (1.0 - 14.6)
Growth differentiation
factor 15 (ng/L)                                       100                     2193 (952 - 5663) 77 2479 (1016 - 7982) 63 2576 (1045 - 7746)
MDS non-RS: TI                                        56                      1777 (731 - 4658) 32 1653 (615 - 5684) 26 1685 (633 - 5736)
MDS non-RS: TD                                      10                     2306 (1218 - 4927) 20 2583 (1725 - 7166) 17 2998 (1398 - 8037)
MDS-RS: TI                                                29                     2619 (996 - 11083) 16 2694 (1223 - 10303) 8 2780 (1331 - 9554)
MDS-RS: TD                                               5                      2893 (2113 - 5370) 9 3866 (830 - 15167) 12 5361 (1053 - 8399)
Soluble transferrin
receptor (mg/L)                                     100                        1.3 (0.7 - 2.8) 78 1.4 (0.7 - 3.0) 62 1.3 (0.8 - 2.7)
MDS non-RS: TI                                        56                         1.2 (0.8 - 2.7) 32 1.4 (0.9 - 2.8) 26 1.2 (0.9 - 2.7)
MDS non-RS: TD                                      10                         1.0 (0.6 - 2.8) 21 1.1 (0.4 - 3.1) 16 1.2 (0.6 - 2.2)
MDS-RS: TI                                                29                         1.6 (0.8 - 3.3) 16 2.0 (1.1 - 2.8) 8 2.2 (1.0 - 2.8)
MDS-RS: TD                                               5                          0.9 (0.4 - 3.1) 9 1.2 (0.6 - 3.1) 12 1.4 (0.4 - 3.6)
Non transferrin
bound iron (μmol/L)                             100                     0.65 (0.14 - 3.03) 77 0.59 (0.15 - 3.64) 65 0.64 (0.14 - 5.42)
MDS non-RS: TI                                        56                      0.41 (0.10 - 1.51) 31 0.42 (0.03 - 0.91) 26 0.50 (0.18 - 1.78)
MDS non-RS: TD                                      10                      0.80 (0.05 - 2.73) 21 0.69 (0.16 - 3.64) 17 1.00 (0.12 - 7.25)
MDS-RS: TI                                                29                      0.88 (0.26 - 3.99) 16 0.70 (0.16 - 3.52) 9 0.52 (0.05 - 5.42)
MDS-RS: TD                                               5                       3.03 (1.90 - 3.40) 9 3.60 (0.15 - 8.64) 13 2.86 (0.46 - 7.57)
Labile plasma
iron (μmol/L)                                          100                     0.09 (0.02 - 0.22) 77 0.13 (0.03 - 0.38) 65 0.13 (0.02 - 0.38)
MDS non-RS: TI                                        56                      0.10 (0.03 - 0.19) 31 0.10 (0.02 - 0.17) 26 0.11 (0.01 - 0.30)
MDS non-RS: TD                                      10                      0.06 (0.01 - 0.18) 21 0.17 (0.06 - 0.38) 17 0.14 (0.02 - 1.08)
MDS-RS: TI                                                29                      0.10 (0.02 - 0.32) 16 0.09 (0.05 - 0.24) 9 0.10 (0.03 - 0.17)
MDS-RS: TD                                               5                       0.08 (0.00 - 0.35) 9 0.47 (0.06 - 1.26) 13 0.19 (0.08 - 1.39)
MDS: Myelodysplastic syndromes; RS: ring sideroblastic; TI: transfusion-independent; TD: transfusion-dependent.
reference range in the TI patients, with the exception of a
minority of RS patients (Online Supplementary Figure S1),
and increased over time in the TD patients, with up to
94.9% in patients with >10 RBC units transfused (Online
Supplementary Table S3). Hepcidin levels increased with
the number of units transfused; in contrast, hepcidin levels
significantly decreased over time in TI MDS-RS patients
(Online Supplementary Table S4). GDF15 levels were not
associated with transfusion status alone, but did increase
over time in TD MDS-RS patients with a median of 2893
ng/L at registration compared to 5361 ng/L at 2 years fol-
low up. 
STFR levels increased significantly (P<0.001) over time
in both TI and TD MDS-RS patients (P=0.01) (Table 2).
STFR levels did not change over time in non-RS MDS
patients. The lowest sTFR levels were observed in patients
who had received more than 10 units (Online
Supplementary Table S3).  TD MDS-RS patients had the
most elevated levels of NTBI and LPI over time (Online
Supplementary Table S3 and S4). 
Correlation between markers of iron overload 
Both elevated NTBI and LPI levels (>LLOD) showed a
threshold effect with TSAT of >70% and >80%, respec-
tively (Figure 1A,B). Detectable LPI levels occurred almost
exclusively in patients with MDS-RS and/or patients who
had received transfusions. NTBI and LPI levels above the
LLOD were mutually positively correlated (r=0.46;
P<0.001). Both NTBI and LPI showed a linear relationship
(P<0.001) with ferritin, but no threshold levels could be
detected (Figure 1C,D). The highest values were observed
in TD MDS patients; subgroup analyses showed mainly a
positive correlation in the TD and/or RS subgroup (Figure
1C,D).
Prognostic impact of iron overload markers 
Time-dependent, multivariate analysis of overall sur-
vival, adjusted for age and IPSS-R risk groups revealed no
significant effect on overall survival for NTBI (HR=0.56,
95%CI 0.21-1.52; P=0.26) and for TSAT (HR=0.91, 95%CI
0.29-2.86; P=0.88) (Table 3, Figure 2B and Online
Supplementary Figure S1).  
Ten out of 19 patients who died during this study had
detectable LPI. The majority (7 patients) died from pro-
gression or MDS-related causes (Online Supplementary
Table S2). Kaplan-Meier curves demonstrate prognostic
impact on survival of detectable LPI levels by transfusion
status (Figure 2), but no significant effect in the multivari-
ate analysis adjusted for age and IPSS-R risk (HR=2.1,
95%CI 0.7-6.2; Table 3). Once LPI was increased in both
TD and TI patients, survival time decreased, with the
greatest impact observed in patients who were TD and
had increased LPI levels (adjusted HR=3.0, 95%CI 0.7-
13.3). Since 41 patients were also treated with erythropoi-
etin stimulating agents (ESA), we repeated the analyses
adjusted for whether or not the patient had been treated
with ESA at each visit (Figure 3). These adjustments did
not significantly alter the magnitude of the risk estimates
on OS (HR=3.0, 95%CI 0.7-13.5) (Table 3).
Because the survival of patients with RS-MDS is usually
considered better than in the non-RS MDS population, we
repeated the analyses in the largest group of 66 non-RS
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Table 3. Cox model of OS by labile plasma iron, non-transferrin bound iron and transferrin saturation along with transfusion status as time varying
variable for all patients (n=100).
Unadjusted Adjusted1 Adjusted2 Adjusted3
Hazard ratio P Hazard ratio P Hazard ratio P Hazard ratio P
(95% CI) (95% CI) (95% CI) (95% CI)
LPI (μmol/L) <LLOD 1 - 1 - 1 - 1 -
≥LLOD 2.2 (0.8 – 6.2) 0.14 2.0 (0.7 – 6.0) 0.21 2.0 (0.7 – 5.8) 0.23 2.0 (0.7 – 6.2) 0.20
LPI<LLOD, TI 1 - 1 - 1 - 1 -
LPI≥LLOD, TI 4.6 (0.5 – 42.4) 0.18 3.2 (0.3 – 30.2) 0.31 3.3 (0.4 – 31.1) 0.30 3.2 (0.3 – 30.4) 0.31
LPI <LLOD, TD 4.1 (1.2 – 13.6) 0.02 2.0 (0.5 – 7.1) 0.30 2.2 (0.6 – 8.1) 0.24 2.0 (0.5 – 7.1) 0.31
LPI ≥LLOD, TD 4.7 (1.1 – 19.7) 0.03 3.0 (0.7 – 13.3) 0.15 3.0 (0.7 – 13.5) 0.14 3.0 (0.7 – 13.4) 0.15
NTBI (μmol/L) <LLOD 1 - 1 - 1 - 1 -
≥LLOD 0.7 (0.3 – 1.7) 0.39 0.6 (0.2 – 1.6) 0.27 0.5 (0.2 – 1.5) 0.24 0.6 (0.2 – 1.5) 0.26
NTBI<LLOD, TI 1 - 1 - 1 - 1 -
NTBI≥LLOD, TI 0.6 (0.1 – 3.8) 0.61 0.7 (0.1 – 4.0) 0.65 0.7 (0.1 – 4.2) 0.67 0.6 (0.1 – 4.0) 0.62
NTBI<LLOD, TD 4.7 (1.1 – 19.0) 0.03 2.6 (0.6 – 11.6) 0.22 3.1 (0.7 – 14.4) 0.14 2.5 (0.6 – 11.5) 0.22
NTBI≥LLOD, TD 2.2 (0.5 – 8.6) 0.27 1.1 (0.3 – 5.0) 0.86 1.2 (0.3 – 5.4) 0.80 1.1 (0.3 – 4.9) 0.89
TSAT <80% 1 - 1 - 1 - 1 -
>80% 1.3 (0.4 – 3.6) 0.66 0.9 (0.3 – 2.9) 0.88 0.9 (0.3 – 2.8) 0.85 1.0 (0.3 – 3.1) 0.97
TSAT <80%, TI 1 - 1 - 1 - 1 -
TSAT≥80%, TI 2.5 (1.0 – 6.2) 0.04 2.3 (0.9 – 5.7) 0.08 2.5 (1.0 – 6.5) 0.05 2.3 (0.9 – 5.9) 0.10
TSAT <80%, TD 1.9 (1.2 – 3.0) 0.003 1.6 (1.0 – 2.5) 0.05 1.7 (1.1 – 2.7) 0.03 1.6 (0.99 – 2.5) 0.053
TSAT≥80%, TD 1.3 (0.9 – 2.0) 0.19 1.1 (0.7 – 1.7) 0.70 1.1 (0.7 – 1.7) 0.67 1.1 (0.7 – 1.7) 0.70
1Adjusted for age at diagnosis and IPSS-R 2Adjusted for age at diagnosis, IPSS-R and ESA treatment status at each visit.3Adjusted for age, IPSS-R and RS status. CI: confidence inter-
val; LLOD: lowest level of detection; LPI: labile plasma iron; TI: transfusion-independent; TD: transfusion-dependent; NTBI: non-transferrin bound iron; TSAT: transferrin saturation.
patients (Table 4). Detectable LPI levels had a remarkable
impact on survival in the whole non-RS group, but the
impact was only significant in the TD subgroup (HR=17.0,
95%CI 2.0-146.6). TSAT levels had a borderline impact on
survival in TI patients.
Six patients received iron chelation in this study (Online
Supplementary Table S1). LPI levels during treatment with
deferasirox decreased below LLOD (4 patients), even in
those patients with high TSAT.  Only 3 patients were
treated with lenalidomide.
Ferritin levels and elevated CRP are time-dependent
variables, which correlate closely with transfusion bur-
den/transfusion intensity, and presumably with infections
(data not shown). Ferritin levels and elevated CRP predict
survival when adjusted for age and IPSS-R group only, but
the prognostic impact is less clear when transfusion inten-
sity was added to the model (data not shown). 
Discussion 
This study among 100 European lower-risk MDS
patients showed that both RBC transfusions and the pres-
ence of RS increased the occurrence of the toxic iron
species NTBI and LPI in serum. Our data on iron parame-
ters over time suggest that body  iron accumulation and
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Table 4. Cox model of OS by labile plasma iron, non-transferrin bound iron and transferrin saturation along with transfusion status as time varying
variable for non-RS patients only (n=66).
Unadjusted Adjusted1 Adjusted2
Hazard ratio P Hazard ratio P Hazard ratio P
(95% CI) (95% CI) (95% CI)
LPI (μmol/L) <LLOD 1 - 1 - 1 -
Elevated 4.9 (1.4 – 16.8) 0.01 5.4 (1.5 – 19.6) 0.01 9.3 (2.0 – 43.3) 0.004
LPI<LLOD, TI 1 - 1 - 1 -
LPI≥LLOD, TI 10.2 (0.9 – 115.4) 0.06 5.3 (0.4 – 68.9) 0.20 5.9 (0.4 – 86.2) 0.19
LPI <LLOD, TD 4.6 (0.9 – 23.5) 0.07 2.0 (0.3 – 12.0) 0.47 1.4 (0.2 – 8.9) 0.70
LPI ≥LLOD, TD 11.8 (1.9 – 74.0) 0.008 10.3 (1.3 – 79.5) 0.03 17.0 (2.0 – 146.6) 0.01
NTBI (μmol/L) <LLOD 1 - 1 - 1 -
Elevated 0.6 (0.2 – 1.9) 0.37 0.6 (0.2 – 2.0) 0.38 0.6 (0.2 – 2.2) 0.46
NTBI<LLOD, TI 1 - 1 - 1 -
NTBI≥LLOD, TI 0.6 (0.1 – 6.9) 0.70 1.1 (0.1 – 14.4) 0.92 1.1 (0.09 – 14.3) 0.92
NTBI<LLOD, TD 5.7 (1.1 – 30.3) 0.04 5.7 (0.8 – 42.2) 0.09 5.4 (0.7 – 43.7) 0.11
NTBI≥LLOD, TD 2.1 (0.4 – 12.3) 0.39 1.4 (0.2 – 8.2) 0.74 1.4 (0.2 – 8.2) 0.74
TSAT <80 1 - 1 - 1 -
Elevated 2.1 (0.6 – 7.8) 0.28 1.1 (0.2 – 5.4) 0.90 1.5 (0.3 – 8.6) 0.63
TSAT <80, TI 1 - 1 - 1 -
TSAT≥80, TI 3.8 (1.1 – 12.7) 0.03 3.7 (0.98 – 13.8) 0.053 3.7 (0.99 – 14.1) 0.052
TSAT <80, TD 1.9 (1.1 – 3.2) 0.02 1.7 (0.9 – 3.2) 0.13 1.6 (0.8 – 3.2) 0.21
TSAT≥80, TD 1.5 (0.9 – 2.5) 0.12 1.1 (0.6 – 1.9) 0.80 1.1 (0.6 – 1.9) 0.77
1Adjusted for age at diagnosis and IPSS-R. 2Adjusted for age at diagnosis, IPSS-R and ESA treatment status at each visit. LLOD: lowest level of detection; LPI: labile plasma iron;
TI: transfusion-independent; TD: transfusion-dependent; TSAT: transferrin saturation; CI: confidence interval. 
Figure 3 Flow diagram of patients treated
with transfusions and erythropoietin stimulat-
ing agents (ESAs). In total, 10 patients
became transfusion-independent after  start-
ing ESA treatment
toxic iron species (NTBI and LPI)  in RS-MDS patients
occur along the axis of ineffective erythropoiesis, charac-
terized by elevated sTFR, increased GDF15, low hepcidin,
and increased circulating and parenchymal iron levels
(Figure 4A). Interestingly we found detectable LPI, but not
NTBI, to be associated with a significantly decreased OS
in non-sideroblastic MDS patients. 
Hepcidin levels were significantly elevated in all TD
patient categories immediately after the initiation of
transfusions, and remained elevated during transfusion
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Figure 4. Proposed pathogenesis of iron toxicity in lower-risk MDS: the impact of ineffective erythropoiesis (A) and of transfusions (B). Ineffective erythropoiesis ,
especially in RS MDS,  results in increased bone marrow production of GDF15 and possibly twisted gastrulation 1 and erythroferrone. These  factors inhibit hepcidin
production by the hepatocytes. Low hepcidin levels increase iron absorption from intestinal mucosa and increase iron release from the macrophages. Eventually,
this may lead to toxic levels of NTBI and LPI, causing damage in solid organs, the immune system and the marrow. During transfusions hepcidin levels increase,
despite higher GDF15 levels, leading to lower iron absorption in the gut. However, transfusions cause massive iron loading of RES-macrophages leading to elevated,
circulating stored iron levels and toxic iron species - despite elevated hepcidin levels - and subsequent toxicities. Figure adapted from ML Cuijpers, et al.6 RS: ring
sideroblastic; GDF15: growth differentiation factor 15; TWSG1: twisted gastrulation 1; LPI: labile plasma iron; NTBI: non-transferrin bound iron; sTFR: soluble trans-
ferrin receptor; RES: reticuloendothelial system; TSAT: transferrin saturations; EPO: erythropoietin.  
A
B
dependency, confirming recent studies in transfused
MDS patients and illustrated in Figure 4B.5,7 However,
the elevated hepcidin levels showed a tendency to
decrease during continued exposure to transfusions. In
addition, sTFR levels decreased over time in TD patients,
compatible with previously reported suppression of ery-
thropoiesis by continued transfusions.20,25 Interestingly,
GDF15 increased over time in TD MDS patients and
especially in those categorized as TD RS-MDS. Increased
GDF15 has previously been associated with ineffective
erythropoiesis, but not with TD-mediated suppression
of erythropoiesis.5 This suggests that TD-mediated sup-
pression of ineffective erythropoiesis may be less effec-
tive during prolonged transfusions. This is supported by
the gradual decline over time of the initially elevated
hepcidin levels during prolonged transfusions. These
data show that previous conflicting observations on the
relationship of GDF15 and hepcidin can be explained by
the impact of transfusions on GDF15 and hepcidin levels,
especially in RS-MDS patients.5 
Hepcidin levels decreased over time in TI patients of
the RS subtype. An earlier study in 107 untransfused
patients observed generally elevated hepcidin levels in
MDS, but low hepcidin/ferritin ratios in the RS subtypes,
compatible with the low hepcidin levels in the RS
patients of our study.39 In addition, RS patients showed
elevated sTFR levels and decreased hepcidin levels com-
pared to TI non-RS at all time points. These observations
confirm the previously reported association between
sTFR and ineffective erythropoiesis, resulting in an
increased uptake of dietary iron and iron release by
macrophages, subsequently leading to increased circulat-
ing iron levels, elevated parenchymal iron stores and
toxic iron species.7 Interestingly, recently developed hep-
cidin agonists prevented low hepcidin-induced toxicity,
preclinically, thus demonstrating the potential of these
compounds to prevent iron loading erythropoietic activ-
ity in MDS, especially in RS-MDS.25,40 Taken together, our
data suggest a worsening over time of the ineffective ery-
thropoiesis along with lower hepcidin levels in RS
patients.41,42 
Elevated NTBI levels could be demonstrated in our
study early in the follow-up period of all patient groups.
In iron loading anemias, such as thalassemia syndromes,
it has been suggested that iron species, such as NTBI and
LPI, serve as early indicators of iron toxicity and as meas-
ures for the effectiveness of iron chelation therapy in
reducing potentially toxic iron molecules in the plas-
ma.7,43 Excess toxic iron species catalyze the cellular gen-
eration of reactive oxygen species (ROS). Oxidative
stress and high TSAT, as in combination with a subse-
quent decrease in cellular antioxidants, may lead to the
oxidation of lipids, proteins and DNA, causing cell and
tissue damage.44,45 Biomarkers of oxidative stress have
been found to be increased in patients with MDS and
iron overload.3,46-49 The combination of high serum fer-
ritin levels as well as the presence of NTBI and LPI was
noted to be more frequent in RS patients compared to
non-RS patients in our study. Herein, it is important to
realize that in general practice, including our study,
serum samples are collected immediately prior to trans-
fusions. LPI levels are usually elevated for a few days
after transfusion (except when transferrin is highly satu-
rated) in contrast to the more stable NTBI which have
been reported to have a longer half-life.50,51 These free
iron molecules are easily translocated intracellularly and
cause oxidative stress as shown in thalassemia.33
Oxidative stress may explain why elevated LPI levels are
associated with an increased risk of dying prematurely;
too early to die from causes related to classical iron over-
load in the lungs, liver and heart as observed in young
thalassemia patients after long-term transfusions. 
Less is known about the pathophysiology and tissue
toxicity of iron overload caused by ineffective erythro-
poiesis in MDS. We observed that high NTBI and LPI lev-
els also occurred in RS patients not receiving transfu-
sions, indicating that iron toxicity (oxidative stress) may
also occur in this category of MDS patients (Figure 4),
similar to TI β-thalassemia intermedia, α-thalassemia
(Hb-H disease), and X-linked sideroblastic anemia.52,53 
Previously, we reported that detectable LPI occurred
almost exclusively in samples with TSAT >80%.29
Interestingly, in the study herein, survival of patients
with TSAT >80% was not different from the survival of
patients with a TSAT below this level (Online
Supplementary Figure S1). The lowest hepcidin levels have
been observed in RS patients,5 similar to our observa-
tions. The elevation of LPI in TI patients occurred exclu-
sively in RS patients as expected in view of the low hep-
cidin levels leading to increased serum iron levels,
through increased intestinal iron absorption and
increased iron release from macrophages. Non-RS
patients with SF3B1 mutations may show a similar iron
pathophysiology since they appear to have a similar out-
come compared to RS-MDS patients with SF3B1 muta-
tions.54 In addition, significant relationships were found
between SF3B1 mutations and marrow erythroblasts
(P=0.001) or soluble transferrin receptor factor 15
(P=0.033).11 Our data show that elevated LPI levels - in
contrast to elevated NTBI levels and TSAT - associate
with decreased survival. The risk of dying prematurely in
patients with detectable LPI levels occurred too early in
this study to explain this risk by classical iron overload
due to organ toxicity (lungs, liver and heart) after long
term transfusions, but this indicates a direct effect asso-
ciated with elevated LPI levels. The impact of detectable
LPI was only significant in the large non-RS group, but
the same tendency was observed in the smaller RS sub-
population. This effect was independent of ESA treat-
ment, indicating that the effect of LPI on outcome is not
simply an effect of the interaction of LPI with ESA, as a
previously described outcome modifier.55,56 The widely
used parameter TSAT cannot serve as a parameter to pre-
dict survival. However, TSAT can be used as a pre-
screening method to identify patients who are at risk to
develop detectable LPI levels and associated poor prog-
nosis. This approach may reduce the number of LPI
determinations substantially. 
Ferritin levels have been reported as a prognostic indi-
cator in MDS, but ferritin as a marker of iron toxicity
may be compromised by the stage of MDS, the cumula-
tive transfusional load and its properties as an acute
phase protein.57-59 Moreover, the level of ferritin does not
indicate whether iron is stored in parenchymal cells or in
the reticuloendothelial system (RES), of which the for-
mer is considered to be a more toxic form of iron over-
load. The foregoing is reflected by the weaker correla-
tion of ferritin levels with LPI when compared with the
correlation between TSAT and LPI levels. The positive
correlation between CRP and hepcidin in the study here-
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in suggests that inflammation also influences iron home-
ostasis in some MDS patients, as reported for patients
with other inflammatory diseases.4 Similar to ferritin,
CRP had a significant impact on survival, potentially
reflecting the impact of infections and autoimmune dis-
eases on survival in this patient group. Finally, we
demonstrated, in the limited number of patients treated
with iron chelators in the study herein, that LPI levels
decreased below LLOD, even in patients with high TSAT
during treatment with deferasirox. These data corrobo-
rate with the post hoc data from a large chelation study in
MDS.43
In conclusion, we demonstrated a disturbed iron
homeostasis both in transfusion dependent MDS
patients and in the subgroup of transfusion independent
RS patients. This is the first clinical study that identifies
LPI as a relevant marker for the potentially toxic fraction
of iron species and its impact on OS.  Increased LPI levels
were restricted to patients with TSAT percentages
exceeding 80%. However, TSAT exceeding 80% alone
was not prognostic for survival. Therefore, we propose
TSAT as a screening parameter to assess risk for
detectable LPI.  Additional studies are warranted to show
that intervention with iron chelation improves survival,
comorbidities and quality of life in lower-risk MDS
patients by lowering LPI levels.  
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